- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
- Interventions
- DUO Transcatheter Tricuspid Coaptation Valve System
- Device
- Lead sponsor
- CroiValve Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Thousand Oaks, California • Atlanta, Georgia + 11 more
Location Directory
Clinical trials in Minneapolis, Minnesota
This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7875
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 565–576 of 7,875 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
- Interventions
- Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
- Device · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 23
- States / cities
- Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
- Interventions
- sepofarsen, Placebo IVT
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 58
- States / cities
- Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more
- Conditions
- HIV Infections
- Interventions
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Timeline
- 2026 – 2029
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more
- Conditions
- MPS I, MPS IV A, MPS - Mucopolysaccharidosis, MPS IVA
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Orange County
- Other
- Eligibility
- 0 Years to 99 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Orange, California • Minneapolis, Minnesota • St Louis, Missouri
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
- Conditions
- Foot Injury
- Interventions
- Modular Carbon Fiber Custom Dynamic Orthosis (CDO), Mono Carbon Fiber Custom Dynamic Orthosis (CDO)
- Device
- Lead sponsor
- Jason Wilken
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- San Diego, California • Iowa City, Iowa • Minneapolis, Minnesota + 2 more
- Conditions
- Leukemia
- Interventions
- cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
- Conditions
- Obesity, Childhood
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Interventions
- aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more